# INTERCEPT Safety Evaluation on Whole Blood

> **NCT04020224** · NA · WITHDRAWN · sponsor: **Swiss Transfusion SRC**

## Conditions studied

- Safety Issues

## Interventions

- **DEVICE:** Amustaline/GSH pathogen reduction technology
- **DEVICE:** Standard of Care

## Key facts

- **NCT ID:** NCT04020224
- **Lead sponsor:** Swiss Transfusion SRC
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2024-01
- **Primary completion:** 2024-12
- **Final completion:** 2025-03
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Sponsor's decision
- **Last updated:** 2024-03-15

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04020224

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04020224, "INTERCEPT Safety Evaluation on Whole Blood". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04020224. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*